Orakl Oncology, a French company that uses lab-grown tumour models and AI to forecast how cancer drugs will perform in patients, raised $34m in a Series A round announced on 12 November 2026. Maddyness put the round at €30.7m.
Swedish firm Norrsken VC and French firm Singular co-led the oversubscribed round, and InfraVia Growth joined it. New investors Serena, Bpifrance's Patient Autonome Fund, teampact.ventures and Plug and Play also took part, along with existing backers Verve Ventures, Speedinvest and HCVC.
The company said the round brings its total funding to $50m. It did not disclose a valuation.
“For decades, we’ve developed cancer drugs without being able to reliably predict how they will behave in patients”Dr. Fanny Jaulin, CEO and Co-Founder, Orakl Oncology
What Orakl Oncology does
Orakl was founded in 2023 as a spin-out of the French cancer centre Gustave Roussy. Dr. Fanny Jaulin is chief executive and co-founder, Dr. Gustave Ronteix is chief technology officer and Dr. Diane-Laure Pagès is chief operating officer. The company has more than 40 staff, and 30% of them hold PhDs.
Its lab grows small models of patients' tumours, known as organoids, and tests drugs on them. It then links those results with clinical and biological data from the same patients and uses the combined data to train AI models. Drug developers use the output to estimate how a trial is likely to turn out, to find the groups of patients most likely to respond and to check whether a drug target is worth pursuing.
The company says its platform has predicted oncology trial outcomes with 90% accuracy. The Next Web reported that the figure comes from investor Norrsken and that the metric behind it has not been defined. It also reported that an April preprint, which has not been peer-reviewed, tested the model against 23 completed colorectal and pancreatic cancer trials and found its forecasts of progression-free time were off by 0.82 months on average.
Customers and traction
Orakl said that just over a year after it started selling, 18 of the world's 20 largest pharmaceutical companies are in its commercial pipeline, and some early projects have turned into collaborations lasting several years. It is negotiating contracts with more than 15 further cancer centres in Europe, North America and Asia.
According to The Next Web, Orakl won the right in July to evaluate four of Sanofi's cancer drugs. The company has not disclosed revenue.
What the money is for
The company plans to build new AI models and enlarge its AI research team. It also plans to generate five times as much experimental data and to move beyond its current tumour types into lung and gastric cancer. It will open teams in the US and the UK to apply its predictions to more than 10 drug programmes, and it will use the platform to look for new drug targets.
Agate Freimane, a general partner at Norrsken VC, said too many drugs still enter costly trials without a clear idea of which patients will benefit. Jeremy Uzan, co-founder and general partner at Singular, said the firm was continuing to back the team as it grows.
The funding so far
According to Maddyness, Orakl raised a €3m (about $3.2m) seed round in October 2023 from Speedinvest, Verve Ventures and HCVC. Its website links to a December 2024 Tech.eu report on an €11m (about $11.6m) raise. Singular, which co-led the new round, was already an investor.
Company website: orakl-oncology.com
